Revenue
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Axogen, Inc. (AXGN)
Price$48.28Cached quote
Net income
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $225.2M | $187.3M | $159.0M | $138.6M | $127.4M | $112.3M | $106.7M | $83.9M | $60.4M | $41.1M | $27.3M | $16.8M | $10.9M | $7.7M | $4.8M | $3.0M |
| Gross profit | $167.4M | $142.0M | $121.9M | $108.8M | $104.4M | $90.7M | $89.4M | $71.0M | $51.1M | $34.6M | $22.5M | $13.4M | $8.5M | $5.7M | $2.4M | $1.6M |
| Gross margin | 74.31% | 75.79% | 76.64% | 78.51% | 81.99% | 80.78% | 83.74% | 84.60% | 84.59% | 84.27% | 82.26% | 79.53% | 77.71% | 74.49% | 49.96% | 54.10% |
| Research & development | $32.9M | $27.8M | $27.3M | $25.6M | $24.2M | $17.8M | $17.5M | $11.8M | $6.7M | $4.2M | $3.2M | $3.0M | $2.1M | $1.4M | $697,355 | $436,008 |
| Operating expenses | $175.2M | $145.3M | $143.3M | $138.5M | $129.8M | $113.9M | $120.8M | $91.5M | $59.1M | $42.8M | $31.7M | $23.2M | $18.1M | $13.5M | $9.4M | $6.1M |
| Operating income | −$7.8M | −$3.3M | −$21.5M | −$29.7M | −$25.4M | −$23.2M | −$31.4M | −$20.5M | −$8.0M | −$8.1M | −$9.3M | −$9.8M | −$9.6M | −$7.8M | −$7.0M | −$4.5M |
| Operating margin | −3.49% | −1.75% | −13.50% | −21.44% | −19.96% | −20.64% | −29.43% | −24.42% | −13.16% | −19.78% | −33.91% | −58.28% | −87.62% | −101.43% | −143.70% | −149.16% |
| EBITDA | −$1.2M | $3.2M | −$17.2M | −$26.9M | −$22.7M | −$21.7M | −$30.4M | −$19.6M | −$7.4M | −$7.7M | −$9.0M | −$9.6M | −$9.5M | −$7.6M | −$6.7M | −$4.1M |
| EBITDA margin | −0.53% | 1.70% | −10.84% | −19.40% | −17.80% | −19.28% | −28.44% | −23.41% | −12.22% | −18.71% | −32.99% | −57.36% | −86.90% | −98.99% | −138.06% | −137.41% |
| Net income | −$15.7M | −$10.0M | −$21.7M | −$28.9M | −$27.0M | −$23.8M | −$29.1M | −$22.4M | −$10.4M | −$14.4M | −$13.4M | −$17.7M | −$14.6M | −$9.4M | −$9.2M | −$5.4M |
| Net profit margin | −6.97% | −5.32% | −13.66% | −20.89% | −21.19% | −21.18% | −27.30% | −26.68% | −17.29% | −35.06% | −48.87% | −105.31% | −132.97% | −122.44% | −190.11% | −180.50% |
| Basic EPSper basic share | -$0.34 | -$0.23 | -$0.51 | -$0.69 | -$0.65 | -$0.60 | -$0.74 | -$0.60 | -$0.31 | -$0.47 | -$0.51 | -$0.99 | -$1.08 | -$0.85 | -$2.77 | -$8.35 |
| Diluted EPSper diluted share | -$0.34 | -$0.23 | -$0.51 | -$0.69 | -$0.65 | -$0.60 | -$0.74 | -$0.60 | -$0.31 | -$0.47 | -$0.51 | -$0.99 | -$1.08 | -$0.85 | -$2.77 | -$8.35 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 8, 2026Form 4 | Wendell Amy McBrideDirector | SellCommon Stock | 1.6K | $42.60 | $70.2K | 93.8K |
| May 7, 2026Form 4 | JOHNSON JOHNDirector | SellCommon Stock | 11.1K | $43.26 | $478.0K | 0 |
| May 7, 2026Form 4 | Weiler Kathy JohnsonDirector | SellCommon Stock | 16.3K | $44.09 | $720.6K | 0 |
| May 7, 2026Form 4 | Kemp JensChief Marketing Officer | SellCommon Stock | 4.0K | $43.44 | $173.8K | 72.5K |
| May 7, 2026Form 4 | Hartley Lindsey MarieCFO | SellCommon Stock | 573 | $43.67 | $25.0K | 65.1K |
Community posts
Axogen pairs a $200 million BioCircuit acquisition with a share offering
Axogen ($AXGN) agreed to acquire BioCircuit Technologies for $200 million in cash, adding the NerveTape platform for sutureless peripheral-nerve repair. The buyer expects the transaction to support revenue growth and improve adjusted EBITDA ...